Traditionally, correspondence between clinicians and general practitioners is kept secret unless shown or read to the patient by the general practitioner. For most patients there seems to be no good reason for such a closed approach. It has been shown that most patients would welcome clinical information about themselves.' 2
We have investigated whether routine clinic letters might be of interest to the patients concerned and, if so, whether they would wish to see further correspondence.
Subjects, methods, and results
We 
Comment
We found that 96% of patients (181/188) were pleased to receive copies of their outpatient medical correspondence, and 93% of these (169/181) asked for copies of any subsequent letters. No overtly critical comments were received, though the 13 questionnaires that were not returned plus the 19 requests for no further correspondence possibly indicated dissatisfaction. No attempt was made to introduce different style, phraseology, or terminology in the general practitioners' letters. Almost one fifth of patients (34/18 1) said that they did not understand parts of the letter, and some approached their general practitioners for clarification. In diabetic practice this difficulty has been avoided by purposely using a Several authors' errors occurred in this paper by Dr Nawab Qizilbash and others (14 September, p 605). In the results section of the abstract the first two p values quoted (for odds ratios of ischaemic stroke for fibrinogen concentrations >3 6 g/l and for total cholesterol concentrations >6 0 mmol/l) should be p=009.
In the results the fourth sentence of the third paragraph should begin: "Although we had originally intended to recruit twice as many controls as cases, . . ." In tables A1, A2, and A3 in the appendix, in the left hand column under the heading "Fluoxetine"-and also in tables A2 and A3 in the left hand column under the heading "Tricyclic antidepressant"-the subheading "Median (range) maintenance dose (mg)" should be inserted between the subheadings "No of patients" and "Mean (range) days treated" and aligned with the numbers currently following "Median (range) days treated." Then, for example, in table Al "Median (range) maintenance dose (mg)" is aligned with 60 (20-80) and "Median range (days treated" is aligned with 31 (1-43); "Baseline HAMD score," which has subsubheadings, will introduce a blank line.
In table A3, in the column for trial No 17 (reference 23), the correct value for the number of fluoxetine treated patients with emergence of substantial suicidal ideation is 0, not 3, and the correct value for the number of placebo treated patients with emergence of substantial suicidal ideation is 17, not 23.
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